Tag: biosimilars vs generics
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Medications
Archives
Recent-posts
Diacerein vs Alternatives: In‑Depth Comparison for Osteoarthritis
Oct, 25 2025
Ocular Trauma: Chemical Splashes and Immediate First Aid
Dec, 28 2025
FDA Safety Communications Archive: How to Research Historical Drug and Device Warnings
Jan, 2 2026
Myxedema Coma: Recognizing Severe Hypothyroidism and Emergency Protocols
Jul, 3 2026
Acetaminophen vs NSAIDs in Pregnancy: Trimester Safety Guide
Jun, 15 2026